NEW YORK (TheStreet) -- Here is a summary of American Society of Clinical Oncology (ASCO) annual meeting research abstracts released tonight focused on the chronic lymphocytic leukemia (CLL) drugs from Pharmacyclics (PCYC), Gilead Sciences (GILD) and Abbvie (ABBV).
Results from the phase III "RESONATE" study of Imbruvica were not disclosed tonight. The research abstract No. LBA7008 is being withheld for presentation at the ASCO meeting.
Last January, Pharmacyclics and Johnson & Johnson (JNJ) announced the early stopping of the Imbruvica RESONATE study because the primary and secondary endpoints -- progression-free survival and overall survival -- were achieved. The study compared Imbruvica to GlaxoSmithKline's (GSK) Arzerra in CLL patients no longer responding to at least one prior therapy.
Imbruvica is already approved for use in patients with mantle cell lymphoma and CLL following progression on at least one prior treatment.
Abstract no. 7014 summarizes three-year, follow-up data from a separate study of Imbruvica in 132 CLL/SLL patients, both treatment naive and relapsed/refractory. The updated overall response rate was 78% for all-treated patients (84% for treatment naive, 76% for relapsed/refractory.) In the subgroup of harder-to-treat del(17p) patients, the response rate to Imbruvica treatment was 56%. Median duration of response was 25 months.
Abstract no. 7009 evaluates the combination of Imbruvica and GSK's Arzerra in 71 patients with relapsed/refractory CLL/SLL. Three different dosing schedules of Imbruvica and Arzerra were studied, with an overall response rate of 83%. At 12 months, progression-free survival was 89%, 85% and 90% in the three different dosing schedules; 76% of patients continued receiving Imbruvica in an extension study. Two patients moved to a bone marrow transplant.